The Medicines Patent Pool (MPP) governance board announced the appointment of Dr. Marie-Paule Kieny as its new chair, effective September 1, 2017.
Kieny, the World Health Organization (WHO)’s former assistant director-general for health systems and innovation, succeeds Sigrun Møgedal, chair since March 2016 and Charles Clift, the MPP’s founding chairman.
She will lead a nine-member board in guiding the foundation’s voluntary licensing and patent pooling work in HIV, hepatitis C and tuberculosis.
“Marie-Paule Kieny, an internationally renowned health specialist and researcher, is a tremendous addition to the MPP Governance Board,” said Møgedal.
“Under her leadership, we are confident that the MPP will succeed in its overall mission of improving access to medicines for millions of people in low and middle income nations.”
Kieny was appointed assistant director-general of the WHO in October 2010 and led its Innovation, Information, Evidence and Research cluster until 2012, and the Health Systems and Innovation cluster until 30 June 2017.
Prior to these roles, she directed the WHO Initiative for Vaccine Research where her successes included the development and licensing of new vaccines for meningitis A and pandemic influenza for developing countries.
From 2014 to 2016, Kieny led the WHO’s Ebola research activities.
She also conducted the WHO’s R&D response to Zika as well as the preparation of a research and development blueprint to accelerate global preparedness for future epidemics.
“In its short six-years, the MPP has played a valuable role in supporting international public health efforts to increase treatment options for people living with HIV, and is now engaged in tuberculosis and hepatitis C,” said Kieny.
“I am pleased to lend a hand to the organisation during this crucial period in its history, a time when new public health mechanisms such as the MPP are desperately needed to address pressing access to medicines challenges.”
The Medicines Patent Pool is a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low and middle income countries.